Scrip: industry news and insights
Zymeworks Rejects ‘Opportunistic’ Investor Takeover Bid
23 May 2022
Activist investor All Blue wants to mount a takeover, but the biotech’s board is holding out for encouraging pipeline news...
Pfizer Inc., GlaxoSmithKline PLC, Allergan PLC and Eli Lilly & Co. are among big pharma firms facing generic competition to blockbuster brands, while AbbVie Inc. and Roche have got biosimilar rivals to worry about.
New drug launches have increased over the past couple of years, but few have reached blockbuster status yet. Meanwhile, China’s increasing appetite (and willingness to pay) for therapeutic innovation was a positive for several big pharma companies in the first quarter. Scrip’s webinar takes a deep dive into the key issues and trends emerging from industry earnings calls.
Scrip: industry news and insights
23 May 2022
Activist investor All Blue wants to mount a takeover, but the biotech’s board is holding out for encouraging pipeline news...
Scrip: industry news and insights
By Kevin Grogan 23 May 2022
The French major has secured a fourth approval, in eosinophilic esophagitis, for Dupixent, while the EMA is set to make...
Scrip: industry news and insights
By Anju Ghangurde 23 May 2022
Momentum for Dr Reddy’s in China as a string of approvals including for lenalidomide come through, while it appears to...
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: